ArticleFrontiers in endocrinology2026
Case Report: Two infants with hypercalcemia of rare and distinct etiologies.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Hypercalcemia in infancy is rare and often presents with nonspecific clinical signs, making early recognition challenging. This report describes two infants with severe symptomatic hypercalcemia due to distinct etiologies and highlights the diagnostic value of sterile pyuria as an early clinical clue. Case presentation: Both infants presented with nonspecific symptoms, including poor feeding, irritability, constipation, and sterile pyuria. In the first infant the diagnosis of Williams-Beuren syndrome had been established earlier, while the second infant had been previously healthy. Both had demonstrated sonographic evidence of nephrocalcinosis. Laboratory evaluation revealed markedly elevated serum calcium levels (up to 4.73 mmol/L), hypercalciuria, and suppressed PTH concentrations in both cases. Standard treatment of hypercalcemia was ineffective, while a single dose of zoledronic acid led to normalization of calcium levels and complete resolution of symptoms. Subsequent genetic testing in the second infant identified a biallelic pathogenic variant in the Conclusion: Sterile pyuria accompanied by nonspecific symptoms may be an early indicator of hypercalcemia in infants and should prompt calcium evaluation. To our knowledge, this is the first report linking sterile pyuria directly to hypercalcemia in this age group. Zoledronic acid can effectively normalize calcium levels in refractory pediatric hypercalcemia. This report adds to the limited evidence regarding zoledronic acid use in infants with Williams-Beuren syndrome and idiopathic infantile hypercalcemia type 1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.